4 days ago
On September 17, Lucid Group, Inc. (NASDAQ:LCID) and Bolt, a leading European shared mobility platform, announced a strategic partnership to develop and deploy autonomous mobility services across Europe. This sent shares of Lucid Group, Inc. (NASDAQ:LCID) higher, and the stock ended the trading session with gains of nearly 6%.
The partnership will combine Lucid Group, Inc.'s (NASDAQ:LCID) software-defined vehicle platform with Bolt's European data, operating infrastructure, and mobility expertise. The companies will be looking to develop and launch autonomous mobility services at scale, using vehicles based on Lucid Group, Inc.'s (NASDAQ:LCID) upcoming Midsize platform.
Bolt plans to deploy at least 25,000 fully autonomous vehicles across multiple European cities and countries, supporting its ambitious goal of having 100,000 autonomous vehicles on its platform by 2035.
The financial details of the partnership were not disclosed.
The deal comes as Lucid Group, Inc. (NASDAQ:LCID) continues to face significant financial pressure. The company has been pursuing an ambitious expansion strategy. However, its revenue growth has not yet been enough to offset substantial operating losses and the high costs ****** ociated with building its global factories.
#lcid #european #platform #partnership
The partnership will combine Lucid Group, Inc.'s (NASDAQ:LCID) software-defined vehicle platform with Bolt's European data, operating infrastructure, and mobility expertise. The companies will be looking to develop and launch autonomous mobility services at scale, using vehicles based on Lucid Group, Inc.'s (NASDAQ:LCID) upcoming Midsize platform.
Bolt plans to deploy at least 25,000 fully autonomous vehicles across multiple European cities and countries, supporting its ambitious goal of having 100,000 autonomous vehicles on its platform by 2035.
The financial details of the partnership were not disclosed.
The deal comes as Lucid Group, Inc. (NASDAQ:LCID) continues to face significant financial pressure. The company has been pursuing an ambitious expansion strategy. However, its revenue growth has not yet been enough to offset substantial operating losses and the high costs ****** ociated with building its global factories.
#lcid #european #platform #partnership
4 days ago
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion of its own stock during the quarter. But the profit story has moving parts, and a few of them pull in opposite directions.
Start with the gap between profit growth and sales growth. Adjusted operating income rose 17.0% while revenue grew only 5.1%. Much of the help came from gross profit, which jumped 23.2% on an adjusted basis as both segments contributed and the OneOncology acquisition in February lifted margins in the US business. In plain terms, adjusted gross margin widened 61 basis points to 4.16%, so the company keeps more gross profit from every dollar it sells.
The strength was not confined to one corner, either. US Healthcare Solutions grew operating income 15.9% on higher pharmaceutical sales and the OneOncology deal, while specialty volume to health systems and physician groups lifted its revenue. International Healthcare Solutions did better still, with operating income up 20.8% on strength in European distribution and global specialty logistics. Management also put cash to work, completing in one quarter the $1 billion of buybacks it had expected to finish by the close of calendar 2026. The board declared a $0.60 quarterly dividend as well, payable August 31, to holders of record on August 14.
Growth is costing more than it first appears. Adjusted operating expenses jumped 26.8%, faster than adjusted gross profit, because OneOncology brought expenses along with its profits. Even so, adjusted operating income amounts to just 1.46% of revenue, a thin cushion on a business this large. Financing adds weight too. Cencora funded part of the purchase with new senior notes plus variable-rate term loans, and net interest expense rose $58.9 million from a year earlier.
The sales mix carries its own drag. GLP-1 drugs for diabetes and weight loss are adding to revenue, but they earn lower gross margins, so each dollar of that growth is worth less to profit. Meanwhile, an oncology customer Cencora lost in 2025, and lower sales to a large mail order customer both held back US revenue, as did lower manufacturer prices on some brand pharmaceuticals. Cencora is also exploring strategic alternatives for a group of other businesses, and its April divestiture of US Consulting Services trimmed consulting sales.
#adjusted #revenue #august
Start with the gap between profit growth and sales growth. Adjusted operating income rose 17.0% while revenue grew only 5.1%. Much of the help came from gross profit, which jumped 23.2% on an adjusted basis as both segments contributed and the OneOncology acquisition in February lifted margins in the US business. In plain terms, adjusted gross margin widened 61 basis points to 4.16%, so the company keeps more gross profit from every dollar it sells.
The strength was not confined to one corner, either. US Healthcare Solutions grew operating income 15.9% on higher pharmaceutical sales and the OneOncology deal, while specialty volume to health systems and physician groups lifted its revenue. International Healthcare Solutions did better still, with operating income up 20.8% on strength in European distribution and global specialty logistics. Management also put cash to work, completing in one quarter the $1 billion of buybacks it had expected to finish by the close of calendar 2026. The board declared a $0.60 quarterly dividend as well, payable August 31, to holders of record on August 14.
Growth is costing more than it first appears. Adjusted operating expenses jumped 26.8%, faster than adjusted gross profit, because OneOncology brought expenses along with its profits. Even so, adjusted operating income amounts to just 1.46% of revenue, a thin cushion on a business this large. Financing adds weight too. Cencora funded part of the purchase with new senior notes plus variable-rate term loans, and net interest expense rose $58.9 million from a year earlier.
The sales mix carries its own drag. GLP-1 drugs for diabetes and weight loss are adding to revenue, but they earn lower gross margins, so each dollar of that growth is worth less to profit. Meanwhile, an oncology customer Cencora lost in 2025, and lower sales to a large mail order customer both held back US revenue, as did lower manufacturer prices on some brand pharmaceuticals. Cencora is also exploring strategic alternatives for a group of other businesses, and its April divestiture of US Consulting Services trimmed consulting sales.
#adjusted #revenue #august
5 days ago
Phillips 66 (NYSE:PSX) has been on a strong rally this year, posting gains of over 110% since the beginning of 2026. The outperformance has been driven by an unusually sharp surge in global refining margins amid the war in the Middle East, which has significantly tightened the world's refining capacity and reduced supplies of gasoline, diesel, and jet fuel.
Given Phillips 66's substantial outperformance compared to the wider market, investors may be questioning whether the stock's record-setting run has reached its peak. However, the ****** ysts over at BMO Capital see further upside ahead. On September 17, the firm raised its price target on PSX from $260 to $310, while maintaining an 'Outperform' rating on the shares. The target boost implies an upside of 13% from the current levels and even exceeds the stock's all-time high of over $274 achieved earlier this month.
BMO Capital highlighted Phillips 66's integrated business model, noting that it has gained momentum and outperformed its individual segments, supported by strong execution across the portfolio. While Refining and Renewables remain the cyclical leaders, BMO also sees a favorable medium-term growth outlook for the company's Midstream business.
BMO Capital's vote of confidence comes amid a broader optimism surrounding Phillips 66, with ****** ysts from Morgan Stanley, Raymon James, UBS, and several others also improving their respective outlooks on PSX. This suggests that Wall Street expects the ongoing refining upcycle to last longer than previously expected, particularly following the renewed escalations between Iran and the United States.
The supply disruptions now extend beyond the troubled region, as a recent wave of Ukrainian attacks on Russian refineries has further reduced global refining capacity and provided further support to margins.
#further #margins #amid
Given Phillips 66's substantial outperformance compared to the wider market, investors may be questioning whether the stock's record-setting run has reached its peak. However, the ****** ysts over at BMO Capital see further upside ahead. On September 17, the firm raised its price target on PSX from $260 to $310, while maintaining an 'Outperform' rating on the shares. The target boost implies an upside of 13% from the current levels and even exceeds the stock's all-time high of over $274 achieved earlier this month.
BMO Capital highlighted Phillips 66's integrated business model, noting that it has gained momentum and outperformed its individual segments, supported by strong execution across the portfolio. While Refining and Renewables remain the cyclical leaders, BMO also sees a favorable medium-term growth outlook for the company's Midstream business.
BMO Capital's vote of confidence comes amid a broader optimism surrounding Phillips 66, with ****** ysts from Morgan Stanley, Raymon James, UBS, and several others also improving their respective outlooks on PSX. This suggests that Wall Street expects the ongoing refining upcycle to last longer than previously expected, particularly following the renewed escalations between Iran and the United States.
The supply disruptions now extend beyond the troubled region, as a recent wave of Ukrainian attacks on Russian refineries has further reduced global refining capacity and provided further support to margins.
#further #margins #amid
5 days ago
Marathon Petroleum Corporation (NYSE:MPC) has substantially outperformed the wider market this year, supported by an unusually sharp surge in global refining margins as the prolonged Iran crisis has significantly tightened global refining capacity and reduced supplies of gasoline, diesel, and jet fuel.
With Marathon up by over 150% since the beginning of 2026, there are now concerns that the stock may have topped out. However, the ****** ysts over at Morgan Stanley are convinced that the rally still has further room to run. On September 14, Morgan Stanley ****** yst Joe Laetsch significantly raised the firm's price target on MPC from $265 to $453, while reaffirming an 'Overweight' rating on the shares.
The target boost reflects an upside of over 9% from the current price level and even exceeds the stock's record high of just under $411 per share achieved earlier this month. The Morgan Stanley update comes amid broader Wall Street optimism surrounding the American refining giant, with ****** ysts from Raymon James, UBS, and several others also improving their respective outlooks on MPC.
Morgan Stanley's vote of confidence suggests that Wall Street expects the ongoing refining upcycle to last longer than previously expected, especially given the fresh wave of attacks between Washington and Tehran. Even if the conflict in the Middle East subsides, the region's refined fuel output is expected to remain relatively tight, since the damaged or idled refineries in the Middle East are likely to take some time to return to full operations.
As the largest refiner by volume in the United States, Marathon has significant operating leverage to capitalize on the current high-margin environment. The company already demonstrated its ability to translate the high crack spreads into material earnings when it delivered an almost fourfold increase in profits in the second quarter.
#morgan #marathon #stanley #middle
With Marathon up by over 150% since the beginning of 2026, there are now concerns that the stock may have topped out. However, the ****** ysts over at Morgan Stanley are convinced that the rally still has further room to run. On September 14, Morgan Stanley ****** yst Joe Laetsch significantly raised the firm's price target on MPC from $265 to $453, while reaffirming an 'Overweight' rating on the shares.
The target boost reflects an upside of over 9% from the current price level and even exceeds the stock's record high of just under $411 per share achieved earlier this month. The Morgan Stanley update comes amid broader Wall Street optimism surrounding the American refining giant, with ****** ysts from Raymon James, UBS, and several others also improving their respective outlooks on MPC.
Morgan Stanley's vote of confidence suggests that Wall Street expects the ongoing refining upcycle to last longer than previously expected, especially given the fresh wave of attacks between Washington and Tehran. Even if the conflict in the Middle East subsides, the region's refined fuel output is expected to remain relatively tight, since the damaged or idled refineries in the Middle East are likely to take some time to return to full operations.
As the largest refiner by volume in the United States, Marathon has significant operating leverage to capitalize on the current high-margin environment. The company already demonstrated its ability to translate the high crack spreads into material earnings when it delivered an almost fourfold increase in profits in the second quarter.
#morgan #marathon #stanley #middle
5 days ago
Valero Energy Corporation (NYSE:VLO) has been on a strong rally, posting gains of over 140% since the beginning of 2026. The strong performance is fuelled by an unusually sharp surge in global refining margins as the ongoing disruptions have significantly reduced the world's refining capacity and tightened supplies of gasoline, diesel, and jet fuel.
While there are now investor concerns that the stock may have topped out, Wall Street sees further upside ahead. On September 14, Morgan Stanley ******* yst Joe Laetsch significantly boosted the firm's price target on VLO from $255 to $411, while maintaining an 'Equal Weight' rating on the shares. The revised target implies an upside of almost 4% from the current levels and even exceeds the stock's all-time high of just under $400 per share.
The higher price objective is supported by the possibility that Valero can translate the favorable refining environment into material earnings and cash flows. The company did exactly that in the second quarter, when it posted its highest-ever Q2 profit and topped Wall Street expectations.
It seems like the high-margin environment is here to stay following a fresh wave of attacks between the US and Iran. Even if the attacks stop and a potential peace agreement is achieved, the damaged or idled refineries in the Middle East are likely to take some time to return to full operations, keeping refined-fuel markets relatively tight. Notably, the supply disruptions also extend beyond the troubled region, as a recent series of Ukrainian strikes on Russian refineries has further constrained global refining capacity.
Valero's FCC Unit optimization project at its St. Charles Refinery will allow it to capitalize even further on the high-priced environment. Expected to be completed in the third quarter, the $230 million initiative will help enhance the facility's ability to produce high-value products.
#even #environment #wall #strong
While there are now investor concerns that the stock may have topped out, Wall Street sees further upside ahead. On September 14, Morgan Stanley ******* yst Joe Laetsch significantly boosted the firm's price target on VLO from $255 to $411, while maintaining an 'Equal Weight' rating on the shares. The revised target implies an upside of almost 4% from the current levels and even exceeds the stock's all-time high of just under $400 per share.
The higher price objective is supported by the possibility that Valero can translate the favorable refining environment into material earnings and cash flows. The company did exactly that in the second quarter, when it posted its highest-ever Q2 profit and topped Wall Street expectations.
It seems like the high-margin environment is here to stay following a fresh wave of attacks between the US and Iran. Even if the attacks stop and a potential peace agreement is achieved, the damaged or idled refineries in the Middle East are likely to take some time to return to full operations, keeping refined-fuel markets relatively tight. Notably, the supply disruptions also extend beyond the troubled region, as a recent series of Ukrainian strikes on Russian refineries has further constrained global refining capacity.
Valero's FCC Unit optimization project at its St. Charles Refinery will allow it to capitalize even further on the high-priced environment. Expected to be completed in the third quarter, the $230 million initiative will help enhance the facility's ability to produce high-value products.
#even #environment #wall #strong
5 days ago
Ukrainian forces fired more than 1,000 drones at Russia overnight, including hundreds that were launched toward Moscow, officials said Sunday as the Kremlin was wrapping up the third and last day of its parliamentary elections.
Moscow's mayor described the wave of drones as the "largest ever" attack on the Russian capital and said there had been damage to a Moscow oil refinery and a residential building.
Across the wider Moscow region, the attack killed two people and wounded 20, local Gov. Andrei Vorobyov said. The dead were a 74-year-old man and a 44-year-old woman, he said.
Writing on social media, Ukrainian President Volodymyr Zelenskyy said that Kyiv had used a range of missiles and drones in the attack — including Ukraine's domestically made Flamingo and Pelican missiles — to hit oil and logistics facilities.
"These are billions of dollars that sustain the war machine," Zelenskyy said, referring to the financial pressure that Kyiv hopes to put on Russia's economy.
#Russia
Moscow's mayor described the wave of drones as the "largest ever" attack on the Russian capital and said there had been damage to a Moscow oil refinery and a residential building.
Across the wider Moscow region, the attack killed two people and wounded 20, local Gov. Andrei Vorobyov said. The dead were a 74-year-old man and a 44-year-old woman, he said.
Writing on social media, Ukrainian President Volodymyr Zelenskyy said that Kyiv had used a range of missiles and drones in the attack — including Ukraine's domestically made Flamingo and Pelican missiles — to hit oil and logistics facilities.
"These are billions of dollars that sustain the war machine," Zelenskyy said, referring to the financial pressure that Kyiv hopes to put on Russia's economy.
#Russia
5 days ago
JEPI, DIVO, and GPIX each pay near 8% monthly yields while growing share price by writing calls on only a portion of holdings.
GPIX has beaten SPY with an 80% return since its 2023 launch by capping its options overlay at just 25 to 75% of the portfolio.
DIVO's tactical options sleeve delivers a lower 6% yield but drives 72% five-year price appreciation, nearly matching SPY's gains.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Covered call ETFs have a reputation problem. For years, the category was defined by funds like QYLD and XYLD that wrote at-the-money calls on entire index portfolios, harvested rich premiums, and quietly bled principal every time markets rallied. Investors got their monthly check and watched their share price drift lower. That is the trap worth avoiding.
#gpix #calls #lower #years
GPIX has beaten SPY with an 80% return since its 2023 launch by capping its options overlay at just 25 to 75% of the portfolio.
DIVO's tactical options sleeve delivers a lower 6% yield but drives 72% five-year price appreciation, nearly matching SPY's gains.
Two retirees, same $1 million, same 4% rule, buy one finished with $1.4 million, the other hit $0 in 12 years. Our free reader guide explains the flaw that separated them, and the income-first method built to avoid it.
Covered call ETFs have a reputation problem. For years, the category was defined by funds like QYLD and XYLD that wrote at-the-money calls on entire index portfolios, harvested rich premiums, and quietly bled principal every time markets rallied. Investors got their monthly check and watched their share price drift lower. That is the trap worth avoiding.
#gpix #calls #lower #years
5 days ago
Credit card companies are racing to claim a place at the checkout when AI agents start shopping on behalf of consumers—even as shoppers remain skeptical of letting bots spend their money.
Mastercard rolled out a payment option Thursday that lets people give an AI agent a virtual card and allow it to buy things online without checking in before each purchase. Cardholders can limit how much it spends, restrict which retailers it buys from, or require approval before checkout.
"This is a land grab for infrastructure standards," Phil Bruno, chief strategy and growth officer at payments company ACI Worldwide, told Fortune. "If they set the standards for agentic commerce, they can keep the commerce in their environments for decades to come."
Rival Visa partnered with Alchemy earlier this year and has also announced its own AI shopping and payment product, Visa Intelligent Commerce, which the company says is still being deployed. Similarly, Meta has Muse, which can search for products and navigate checkout, but presents the purchase for the user's final approval.
It seems, though, that shoppers appear far more interested in using AI to find a deal than letting it pay. Just 7% of U.S. and U.K. consumers surveyed who buy fashion items said they would allow an AI ***** istant to make purchases without approval under predefined conditions, according to research commissioned by ACI Worldwide. More than half said they were uncomfortable allowing AI to purchase on their behalf.
#purchase #consumers
Mastercard rolled out a payment option Thursday that lets people give an AI agent a virtual card and allow it to buy things online without checking in before each purchase. Cardholders can limit how much it spends, restrict which retailers it buys from, or require approval before checkout.
"This is a land grab for infrastructure standards," Phil Bruno, chief strategy and growth officer at payments company ACI Worldwide, told Fortune. "If they set the standards for agentic commerce, they can keep the commerce in their environments for decades to come."
Rival Visa partnered with Alchemy earlier this year and has also announced its own AI shopping and payment product, Visa Intelligent Commerce, which the company says is still being deployed. Similarly, Meta has Muse, which can search for products and navigate checkout, but presents the purchase for the user's final approval.
It seems, though, that shoppers appear far more interested in using AI to find a deal than letting it pay. Just 7% of U.S. and U.K. consumers surveyed who buy fashion items said they would allow an AI ***** istant to make purchases without approval under predefined conditions, according to research commissioned by ACI Worldwide. More than half said they were uncomfortable allowing AI to purchase on their behalf.
#purchase #consumers
5 days ago
Johnson & Johnson (JNJ) stock has returned about 57% over the past year, against about 17% for the S&P 500. On the earnings it has already banked, that price looks expensive. But those earnings carry STELARA, which is losing share to biosimilar competition. What looks dear on earnings already reported comes down sharply on the earnings ***** ysts expect.
At about $270 a share, Johnson & Johnson trades at about 28.3 times its trailing earnings. That figure sits on adjusted earnings: normalized net income with stock-based compensation added back, meant to sit closer to the basis ***** ysts use in their forecasts than a GAAP figure would, though the two measures are not defined identically. Measured as market value against consensus net income, the multiple on fiscal 2026 earnings is about 24.1 times, and on the earnings expected for 2027 it is about 20.9 times.
Those trailing twelve months were not a clean run. STELARA cost Johnson & Johnson about 460 basis points of operational sales growth in the second quarter of 2026. Strip it out and the company grew double digits in that quarter on the same basis, on management's own account.
The trailing multiple measures today's price against a period burdened by slowing STELARA revenue. The rest of the portfolio kept growing. Revenue over the trailing twelve months is close to $98 billion, and the company has 28 products and platforms that each sell more than $1 billion a year.
Immunology shows both sides at once. TREMFYA grew 71% in the second quarter of 2026, and it remains the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis. STELARA is shrinking under biosimilars in that same segment.
#johnson #earnings
At about $270 a share, Johnson & Johnson trades at about 28.3 times its trailing earnings. That figure sits on adjusted earnings: normalized net income with stock-based compensation added back, meant to sit closer to the basis ***** ysts use in their forecasts than a GAAP figure would, though the two measures are not defined identically. Measured as market value against consensus net income, the multiple on fiscal 2026 earnings is about 24.1 times, and on the earnings expected for 2027 it is about 20.9 times.
Those trailing twelve months were not a clean run. STELARA cost Johnson & Johnson about 460 basis points of operational sales growth in the second quarter of 2026. Strip it out and the company grew double digits in that quarter on the same basis, on management's own account.
The trailing multiple measures today's price against a period burdened by slowing STELARA revenue. The rest of the portfolio kept growing. Revenue over the trailing twelve months is close to $98 billion, and the company has 28 products and platforms that each sell more than $1 billion a year.
Immunology shows both sides at once. TREMFYA grew 71% in the second quarter of 2026, and it remains the fastest-growing advanced therapy in both Crohn's disease and ulcerative colitis. STELARA is shrinking under biosimilars in that same segment.
#johnson #earnings
6 days ago
Choosing between a niche equipment provider and a diversified industry **** an requires balancing high growth potential against established stability. Here is how Aehr Test Systems (NASDAQ:AEHR) and KLA (NASDAQ:KLAC) compare for investors.
Aehr Test Systems focuses on specific stress-testing solutions for power semiconductors and memory, while KLA provides broad process control tools used across the entire chip-making industry. While they both operate in the same sector, their scale and risk profiles differ significantly, making them attractive to different types of portfolios.
Aehr Test Systems designs and sells specialized equipment for the testing and stabilization of semiconductor products in various forms, including wafers and singulated dies. The company focuses on the high-growth silicon carbide market for electric vehicles and high-bandwidth memory for artificial intelligence infrastructure. In its 2026 fiscal year (FY), which ended May 29, its five largest customers accounted for nearly 70% of net sales, and customer concentration like this adds a layer of risk to the business.
In FY 2026, revenue reached $50.0 million, representing a decline of 15.2% compared to the previous year. This contraction followed a period of higher operating costs, resulting in a net loss of $7.1 million for the period. The net margin, which represents the percentage of revenue remaining as profit after all expenses, was -14.3% in the latest fiscal year.
As of its May 2026 balance sheet, the debt-to-equity ratio is zero, indicating that the company has no debt relative to its shareholder equity. The current ratio, which measures a company's ability to cover short-term liabilities with short-term **** ets, is 10.3x. Free cash flow, defined as cash from operations minus capital expenditures, was a negative $5.4 million for the fiscal year ended in May.
#year #equipment
Aehr Test Systems focuses on specific stress-testing solutions for power semiconductors and memory, while KLA provides broad process control tools used across the entire chip-making industry. While they both operate in the same sector, their scale and risk profiles differ significantly, making them attractive to different types of portfolios.
Aehr Test Systems designs and sells specialized equipment for the testing and stabilization of semiconductor products in various forms, including wafers and singulated dies. The company focuses on the high-growth silicon carbide market for electric vehicles and high-bandwidth memory for artificial intelligence infrastructure. In its 2026 fiscal year (FY), which ended May 29, its five largest customers accounted for nearly 70% of net sales, and customer concentration like this adds a layer of risk to the business.
In FY 2026, revenue reached $50.0 million, representing a decline of 15.2% compared to the previous year. This contraction followed a period of higher operating costs, resulting in a net loss of $7.1 million for the period. The net margin, which represents the percentage of revenue remaining as profit after all expenses, was -14.3% in the latest fiscal year.
As of its May 2026 balance sheet, the debt-to-equity ratio is zero, indicating that the company has no debt relative to its shareholder equity. The current ratio, which measures a company's ability to cover short-term liabilities with short-term **** ets, is 10.3x. Free cash flow, defined as cash from operations minus capital expenditures, was a negative $5.4 million for the fiscal year ended in May.
#year #equipment
6 days ago
Interested in Keysight Technologies Inc.? Here are five stocks we like better.
AI data-center demand is driving strong growth in Keysight's wireline business, particularly around 1.6T and emerging 3.2T networking, silicon photonics, co-packaged optics and system-level testing.
Demand currently exceeds supply, with Keysight expanding manufacturing capacity, supplier agreements and component sourcing; revenue beyond its typical order-to-revenue window was approaching $100 million.
Keysight expects additional growth from 6G, aerospace and defense, semiconductors and software-defined vehicles. The company anticipates 6G acceleration in the first half of 2028 and plans to maintain investment while targeting incremental margins of at least 40% when growth exceeds 5%.
3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
#exceeds #lesser
AI data-center demand is driving strong growth in Keysight's wireline business, particularly around 1.6T and emerging 3.2T networking, silicon photonics, co-packaged optics and system-level testing.
Demand currently exceeds supply, with Keysight expanding manufacturing capacity, supplier agreements and component sourcing; revenue beyond its typical order-to-revenue window was approaching $100 million.
Keysight expects additional growth from 6G, aerospace and defense, semiconductors and software-defined vehicles. The company anticipates 6G acceleration in the first half of 2028 and plans to maintain investment while targeting incremental margins of at least 40% when growth exceeds 5%.
3 Lesser-Known Quantum Plays the Market May Be Overlooking Right Now
#exceeds #lesser
6 days ago
On September 15, Arthur J. Gallagher & Co. (NYSE:AJG) announced that it had bought McMillan Insurance & Bonding Inc., an Englewood, Colorado, firm that operates as Innovise Business Consultants. Gallagher did not say what it paid. On its own, the deal is a footnote. But it is one of many, and the way those deals show up in earnings is where the debate over this stock really lives.
On July 30, Gallagher reported results for the quarter ended June 30, and the top line was hard to argue with. Revenue from its combined Brokerage and Risk Management businesses grew 24%, and organic growth, which leaves out acquisitions, was 6%. That second number shows clients are staying and spending. It was not confined to one corner, either, since organic fees in the risk management arm rose 12%. Management adds that retention is strong and customers want broader help from the platform. Adjusted earnings per share climbed to $2.84 from $2.30, which means growth is reaching profit once one-time acquisition costs are set aside.
Innovise fits the pattern. It sells surety bonds and commercial insurance brokerage with a focus on manufacturing, energy, construction and real estate, and Chairman and CEO J. Patrick Gallagher, Jr. said that niche expertise adds depth in Colorado. Jason McMillan's team will move into Gallagher's Denver office and work under Bret VanderVoort, who oversees retail property/casualty brokerage for the Western Zone. Buying specialists and folding them into existing offices is a repeatable playbook, and Gallagher closed 14 brokerage acquisitions in the first six months of 2026.
Now look at reported earnings, because that is where you see the cost. Diluted earnings per share fell to $1.25, from $1.40 in the second quarter of 2025, even though revenue jumped. Much of the gap between reported and adjusted results is the price of buying growth. Amortization of acquired intangibles alone weighs on brokerage net earnings by $218 million, up from $130 million a year ago, and integration costs rose as well. Adjusted figures set those aside, but they are real expenses, and they keep landing as long as Gallagher keeps buying.
Margins tell a similar story. The brokerage segment's adjusted EBITDAC margin, a stand-in for operating profit, slipped to 33.3% from 36.1%. Gallagher points to last year's interest income on cash raised for the ***** uredPartners deal, which closed in the third quarter of 2025, plus seasonality and newly added tuck-ins. That is a fair explanation. But the debt behind the deal is still here, including $9.55 billion of public debt, plus more in private placements and on a credit line. And the deal flow is thinner: brokerage acquisitions closed in the first six months of 2026 carried $107 million of annualized revenue, versus $354 million a year earlier, which puts more weight on organic growth.
#Growth
On July 30, Gallagher reported results for the quarter ended June 30, and the top line was hard to argue with. Revenue from its combined Brokerage and Risk Management businesses grew 24%, and organic growth, which leaves out acquisitions, was 6%. That second number shows clients are staying and spending. It was not confined to one corner, either, since organic fees in the risk management arm rose 12%. Management adds that retention is strong and customers want broader help from the platform. Adjusted earnings per share climbed to $2.84 from $2.30, which means growth is reaching profit once one-time acquisition costs are set aside.
Innovise fits the pattern. It sells surety bonds and commercial insurance brokerage with a focus on manufacturing, energy, construction and real estate, and Chairman and CEO J. Patrick Gallagher, Jr. said that niche expertise adds depth in Colorado. Jason McMillan's team will move into Gallagher's Denver office and work under Bret VanderVoort, who oversees retail property/casualty brokerage for the Western Zone. Buying specialists and folding them into existing offices is a repeatable playbook, and Gallagher closed 14 brokerage acquisitions in the first six months of 2026.
Now look at reported earnings, because that is where you see the cost. Diluted earnings per share fell to $1.25, from $1.40 in the second quarter of 2025, even though revenue jumped. Much of the gap between reported and adjusted results is the price of buying growth. Amortization of acquired intangibles alone weighs on brokerage net earnings by $218 million, up from $130 million a year ago, and integration costs rose as well. Adjusted figures set those aside, but they are real expenses, and they keep landing as long as Gallagher keeps buying.
Margins tell a similar story. The brokerage segment's adjusted EBITDAC margin, a stand-in for operating profit, slipped to 33.3% from 36.1%. Gallagher points to last year's interest income on cash raised for the ***** uredPartners deal, which closed in the third quarter of 2025, plus seasonality and newly added tuck-ins. That is a fair explanation. But the debt behind the deal is still here, including $9.55 billion of public debt, plus more in private placements and on a credit line. And the deal flow is thinner: brokerage acquisitions closed in the first six months of 2026 carried $107 million of annualized revenue, versus $354 million a year earlier, which puts more weight on organic growth.
#Growth
6 days ago
On August 5, Cencora (NYSE:COR) reported results for its fiscal third quarter, which closed on June 30, and the headline numbers looked clean. Revenue rose 5.1% to $84.8 billion, adjusted earnings per share climbed 12.0% to $4.48, and management raised its full-year adjusted EPS outlook to $17.75 to $17.95. The company also repurchased $1 billion of its own stock during the quarter. But the profit story has moving parts, and a few of them pull in opposite directions.
Start with the gap between profit growth and sales growth. Adjusted operating income rose 17.0% while revenue grew only 5.1%. Much of the help came from gross profit, which jumped 23.2% on an adjusted basis as both segments contributed and the OneOncology acquisition in February lifted margins in the US business. In plain terms, adjusted gross margin widened 61 basis points to 4.16%, so the company keeps more gross profit from every dollar it sells.
The strength was not confined to one corner, either. US Healthcare Solutions grew operating income 15.9% on higher pharmaceutical sales and the OneOncology deal, while specialty volume to health systems and physician groups lifted its revenue. International Healthcare Solutions did better still, with operating income up 20.8% on strength in European distribution and global specialty logistics. Management also put cash to work, completing in one quarter the $1 billion of buybacks it had expected to finish by the close of calendar 2026. The board declared a $0.60 quarterly dividend as well, payable August 31, to holders of record on August 14.
Growth is costing more than it first appears. Adjusted operating expenses jumped 26.8%, faster than adjusted gross profit, because OneOncology brought expenses along with its profits. Even so, adjusted operating income amounts to just 1.46% of revenue, a thin cushion on a business this large. Financing adds weight too. Cencora funded part of the purchase with new senior notes plus variable-rate term loans, and net interest expense rose $58.9 million from a year earlier.
The sales mix carries its own drag. GLP-1 drugs for diabetes and weight loss are adding to revenue, but they earn lower gross margins, so each dollar of that growth is worth less to profit. Meanwhile, an oncology customer Cencora lost in 2025, and lower sales to a large mail order customer both held back US revenue, as did lower manufacturer prices on some brand pharmaceuticals. Cencora is also exploring strategic alternatives for a group of other businesses, and its April divestiture of US Consulting Services trimmed consulting sales.
#profit #operating #Growth #august
Start with the gap between profit growth and sales growth. Adjusted operating income rose 17.0% while revenue grew only 5.1%. Much of the help came from gross profit, which jumped 23.2% on an adjusted basis as both segments contributed and the OneOncology acquisition in February lifted margins in the US business. In plain terms, adjusted gross margin widened 61 basis points to 4.16%, so the company keeps more gross profit from every dollar it sells.
The strength was not confined to one corner, either. US Healthcare Solutions grew operating income 15.9% on higher pharmaceutical sales and the OneOncology deal, while specialty volume to health systems and physician groups lifted its revenue. International Healthcare Solutions did better still, with operating income up 20.8% on strength in European distribution and global specialty logistics. Management also put cash to work, completing in one quarter the $1 billion of buybacks it had expected to finish by the close of calendar 2026. The board declared a $0.60 quarterly dividend as well, payable August 31, to holders of record on August 14.
Growth is costing more than it first appears. Adjusted operating expenses jumped 26.8%, faster than adjusted gross profit, because OneOncology brought expenses along with its profits. Even so, adjusted operating income amounts to just 1.46% of revenue, a thin cushion on a business this large. Financing adds weight too. Cencora funded part of the purchase with new senior notes plus variable-rate term loans, and net interest expense rose $58.9 million from a year earlier.
The sales mix carries its own drag. GLP-1 drugs for diabetes and weight loss are adding to revenue, but they earn lower gross margins, so each dollar of that growth is worth less to profit. Meanwhile, an oncology customer Cencora lost in 2025, and lower sales to a large mail order customer both held back US revenue, as did lower manufacturer prices on some brand pharmaceuticals. Cencora is also exploring strategic alternatives for a group of other businesses, and its April divestiture of US Consulting Services trimmed consulting sales.
#profit #operating #Growth #august
6 days ago
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal lands weeks after Jazz posted its highest quarterly revenue ever on August 3, and raised its full-year guidance, so a fresh acquisition now sits on top of a business that was already accelerating. The question for investors is whether that combination adds up to durable growth or just a bigger bill.
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
ABS-1230 targets KCNT1-related epilepsy, a rare and hard-to-treat form of the disease. In an early clinical proof-of-concept trial, children who received the drug experienced meaningful seizure reductions, and preclinical testing showed it inhibited KCNT1 across every pathogenic mutation researchers evaluated, hinting it could work across the whole patient population rather than a narrow subset. The FDA has already granted ABS-1230 Orphan Drug, Rare Pediatric Disease and Fast Track designations, and accepted it into the agency's Rare Disease Evidence Principles process, a set of regulatory advantages that can speed a drug toward approval.
The acquisition also arrives while Jazz's existing business is firing on multiple cylinders. Second-quarter revenue climbed 16% year over year to $1.2 billion, the company's highest quarterly total on record, and management raised full-year 2026 revenue guidance to a range of $4.6 billion to $4.75 billion. Growth was not confined to one product. Xywav sales rose 13% to $471 million on 525 net new patients, Epidiolex grew 16% to $292 million, and Zepzelca jumped 42% to $106 million. Zanidatamab, sold as Ziihera in biliary tract cancer, also received Breakthrough Therapy designation from the FDA for a form of colorectal cancer, adding another avenue for the oncology franchise Jazz has been building beyond its epilepsy and sleep businesses.
None of that came free. The $820 million upfront payment for Actio lands on top of $4.4 billion in long-term debt that Jazz already carried as of June 30, even after the company used part of its cash to repay $1.0 billion of exchangeable notes that matured this year. Cash, equivalents and investments stood at $2.2 billion at that point, meaning the Actio payment alone accounts for a meaningful share of the company's liquid resources.
Jazz's recent history also shows how acquisitions can distort the bottom line before they pay off. A $905.4 million in-process research and development charge tied to the 2025 Chimerix acquisition pushed second-quarter 2025 GAAP earnings to a loss of $11.74 per share, and a smaller $77 million IPR&D charge from the AbCellera and Werewolf deals still dented second-quarter 2026 results. ABS-1230 itself remains early, with only proof-of-concept data in hand and no late-stage trial results yet. The portfolio is not without setbacks, either. Jazz is moving to voluntarily drop the second-line indication for Zepzelca in meta
6 days ago
The temporary closure of the key onshore pipeline Saudi Arabia uses to bypass the Strait of Hormuz has added another shock to an oil market already struggling with six months of Middle East supply disruptions.
And the damage now appears to be more extensive than initially believed.
Three pumping stations along Saudi Arabia's East-West pipeline were damaged in last week's attack, Reuters reported on Thursday, citing satellite imagery and industry sources. Earlier ***** sments had identified damage at two stations. Three sources told Reuters that repairs could take five to six weeks, although partial pumping could resume sooner.
Before the attack, the system was moving between 4 million and 5 million barrels per day (bpd), equivalent to roughly 4%–5% of global oil supply. Its total capacity is around 7 million bpd, including approximately 2 million bpd supplied to refineries.
Saudi Arabia shut the pipeline following multiple attacks on September 10. Satellite imagery previously published by MizarVision showed extensive fire and structural damage around pumping stations along the route.
#million #pumping #arabia
And the damage now appears to be more extensive than initially believed.
Three pumping stations along Saudi Arabia's East-West pipeline were damaged in last week's attack, Reuters reported on Thursday, citing satellite imagery and industry sources. Earlier ***** sments had identified damage at two stations. Three sources told Reuters that repairs could take five to six weeks, although partial pumping could resume sooner.
Before the attack, the system was moving between 4 million and 5 million barrels per day (bpd), equivalent to roughly 4%–5% of global oil supply. Its total capacity is around 7 million bpd, including approximately 2 million bpd supplied to refineries.
Saudi Arabia shut the pipeline following multiple attacks on September 10. Satellite imagery previously published by MizarVision showed extensive fire and structural damage around pumping stations along the route.
#million #pumping #arabia
6 days ago
Crane Company (NYSE:CR) announced a definitive agreement on September 14 to acquire Trillium Flow Technologies' U.S. pump business for approximately $240 million. The operations primarily serve municipal water and wastewater customers and are expected to generate approximately $115 million in full-year revenue. Closing is expected in the fourth quarter, subject to regulatory approvals and customary conditions.
The acquisition would add Floway, Wemco, Roto-Jet and WSP to Process Flow Technologies. Their installed equipment base supports service, repair, retrofit and replacement demand, giving the transaction a recurring-revenue rationale.
Crane Company (NYSE:CR) disclosed a price of approximately 14.6 times estimated 2026 adjusted EBITDA. Adjusted EBITDA is a company-defined non-GAAP measure based on earnings before interest, taxes, depreciation, and amortization, with further adjustments. The announcement did not specify the target's adjustments or provide a GAAP reconciliation.
Water and wastewater systems require reliable pumping equipment throughout their operating lives. An established installed base creates opportunities to sell replacement parts, restore equipment, and upgrade performance long after the original sale.
For Crane Company (NYSE:CR), those customer relationships could make revenue less dependent on winning entirely new projects. Service capability and product familiarity may also help retain customers when equipment eventually needs replacement.
#NYSE
The acquisition would add Floway, Wemco, Roto-Jet and WSP to Process Flow Technologies. Their installed equipment base supports service, repair, retrofit and replacement demand, giving the transaction a recurring-revenue rationale.
Crane Company (NYSE:CR) disclosed a price of approximately 14.6 times estimated 2026 adjusted EBITDA. Adjusted EBITDA is a company-defined non-GAAP measure based on earnings before interest, taxes, depreciation, and amortization, with further adjustments. The announcement did not specify the target's adjustments or provide a GAAP reconciliation.
Water and wastewater systems require reliable pumping equipment throughout their operating lives. An established installed base creates opportunities to sell replacement parts, restore equipment, and upgrade performance long after the original sale.
For Crane Company (NYSE:CR), those customer relationships could make revenue less dependent on winning entirely new projects. Service capability and product familiarity may also help retain customers when equipment eventually needs replacement.
#NYSE
6 days ago
Intuitive Surgical (ISRG), maker of the da Vinci surgical robots, trades at about $382, some 36% below its 52-week high. Even so, you pay about 35.9 times trailing adjusted earnings. That is normalized net income with stock-based compensation added back, a basis meant to sit closer to the one ****** ysts forecast on, though the two are not defined identically. ****** ysts' forecasts run to 2027, the year Intuitive plans to start lowering what customers pay per use on some instruments.
The shares were trading about 11% lower the day after second-quarter results in July showed slower US procedure growth. US da Vinci procedures grew 12% in the second quarter, against 14% in the first. Management pointed to two likely causes, with the CFO noting that some customers say coverage changes are delaying deferrable procedures, alongside a little of the law of large numbers.
What the price still pays for is revenue growing faster than procedures. On the first-quarter call, the CFO credited that largely to da Vinci 5 and its higher pricing. More than half of the da Vinci systems Intuitive placed in the second quarter were da Vinci 5.
On ****** ysts' 2026 estimates, today's price is about 35.1 times earnings. On their 2027 estimates, it is about 31.4 times. The revenue forecast behind that looks modest: about 13.1% growth a year through 2027, against 20.7% growth over the past twelve months.
Consensus has earnings and revenue growing at a similar pace between 2026 and 2027, so margins hold roughly steady. Intuitive enters that stretch with an operating margin of 31.3% over the past twelve months, above its three-year average of 27.7%.
#intuitive #analysts #year #procedures
The shares were trading about 11% lower the day after second-quarter results in July showed slower US procedure growth. US da Vinci procedures grew 12% in the second quarter, against 14% in the first. Management pointed to two likely causes, with the CFO noting that some customers say coverage changes are delaying deferrable procedures, alongside a little of the law of large numbers.
What the price still pays for is revenue growing faster than procedures. On the first-quarter call, the CFO credited that largely to da Vinci 5 and its higher pricing. More than half of the da Vinci systems Intuitive placed in the second quarter were da Vinci 5.
On ****** ysts' 2026 estimates, today's price is about 35.1 times earnings. On their 2027 estimates, it is about 31.4 times. The revenue forecast behind that looks modest: about 13.1% growth a year through 2027, against 20.7% growth over the past twelve months.
Consensus has earnings and revenue growing at a similar pace between 2026 and 2027, so margins hold roughly steady. Intuitive enters that stretch with an operating margin of 31.3% over the past twelve months, above its three-year average of 27.7%.
#intuitive #analysts #year #procedures
6 days ago
October WTI crude oil (CLV26) closed down -0.52 (-0.51%) on Thursday, and October RBOB gasoline (RBV26) closed up +0.0223 (+0.64%).
Crude oil and gasoline prices settled mixed on Thursday, with gasoline climbing to a 1.75-month nearest-futures high. Crude prices fell on Thursday amid signs that supply disruptions in the Middle East are set to ease, potentially boosting global oil supplies. However, gasoline prices rose on Thursday after Goldman Sachs said that gasoline supplies are set to tighten as refiners switch output from gasoline to diesel due to record-high diesel prices.
Crude Oil Prices Sharply Lower as Middle East Disruptions Ease
Crude Oil Prices Retreat as Supply Fears Ease
If You Missed the Nancy Pelosi Rally, Here's the Case for Buying Bloom Energy Stock Now
#october
Crude oil and gasoline prices settled mixed on Thursday, with gasoline climbing to a 1.75-month nearest-futures high. Crude prices fell on Thursday amid signs that supply disruptions in the Middle East are set to ease, potentially boosting global oil supplies. However, gasoline prices rose on Thursday after Goldman Sachs said that gasoline supplies are set to tighten as refiners switch output from gasoline to diesel due to record-high diesel prices.
Crude Oil Prices Sharply Lower as Middle East Disruptions Ease
Crude Oil Prices Retreat as Supply Fears Ease
If You Missed the Nancy Pelosi Rally, Here's the Case for Buying Bloom Energy Stock Now
#october
6 days ago
Logistic Properties of the Americas (NYSEAMERICAN:LPA) moved closer to selling Parque Logístico Lima Sur after Peru's antitrust authority, INDECOPI, approved the transaction on September 11. FIBRA Prime would acquire the entire 1.3-million-square-foot logistics park for $145 million. Customary administrative closing matters remain outstanding.
Management expects approximately $85 million of net proceeds after debt repayment and before taxes, with Mexico the intended destination. Approval advances the financing of that expansion, while the investment case rests on replacing an established income stream.
Lima Sur generated $10.3 million of cash net operating income, or cash NOI, during the 12 months ended March 31, 2026. Cash NOI is a company-defined non-IFRS measure of property income after operating expenses, adjusted to remove straight-line rental accounting. It excludes corporate overhead, financing costs, income taxes, and other non-property items.
Logistic Properties of the Americas (NYSEAMERICAN:LPA) has demonstrated an ability to develop, lease and operate logistics ***** ets. Second-quarter revenue increased 26.1% to $14.7 million, while stabilized portfolio occupancy reached 100% as of June 30.
Mexico already contributes revenue. Two properties acquired in Puebla in August 2025 generated approximately $0.5 million during the second quarter. That provides an operating foothold for deploying proceeds.
#cash #logistic #nyseamerican #Mexico
Management expects approximately $85 million of net proceeds after debt repayment and before taxes, with Mexico the intended destination. Approval advances the financing of that expansion, while the investment case rests on replacing an established income stream.
Lima Sur generated $10.3 million of cash net operating income, or cash NOI, during the 12 months ended March 31, 2026. Cash NOI is a company-defined non-IFRS measure of property income after operating expenses, adjusted to remove straight-line rental accounting. It excludes corporate overhead, financing costs, income taxes, and other non-property items.
Logistic Properties of the Americas (NYSEAMERICAN:LPA) has demonstrated an ability to develop, lease and operate logistics ***** ets. Second-quarter revenue increased 26.1% to $14.7 million, while stabilized portfolio occupancy reached 100% as of June 30.
Mexico already contributes revenue. Two properties acquired in Puebla in August 2025 generated approximately $0.5 million during the second quarter. That provides an operating foothold for deploying proceeds.
#cash #logistic #nyseamerican #Mexico
6 days ago
In late 2022, OpenAI released ChatGPT, and within months the bottom rung of the tech-industry career ladder started to disappear. Graduates who majored in computer science and other AI-exposed fields are increasingly missing out on the jobs they trained for, and a chunk of them are landing behind restaurant counters and retail registers instead, according to two Census Bureau papers.
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
An April 2026 Census paper tracked matched employer-employee records and found that hiring of workers ages 22 to 24 fell sharply in the industries most exposed to AI, while hiring in less-exposed industries held steady. Employment for early-career workers in the most AI-exposed fifth of industries dropped 12% over the ten quarters after ChatGPT's release. Lee Tucker, one of the coauthors of the paper, said "the decline in hires is the primary cause" of that rate of unemployment, not people losing jobs they already had.
That mattered most for one type of graduate. The most AI-exposed industries, Tucker found, cluster heavily around software and information-technology work, which are the very fields computer science and other highly AI-exposed majors are built to feed into.
A second paper from last week, also coauthored by Tucker, follows the graduates of the most AI-exposed decile of college majors. Their odds of holding a job one quarter after graduation fell by five percentage points, and full-quarter initial earnings dropped 13% following ChatGPT's release. A 13% earnings decline is roughly the size economists would expect from graduating into a severe recession—except there wasn't one, since the rest of the labor market held up fine.
Young grads still need to work and still have jobs, even if they've received highly exposed degrees. So the decline in earnings is less about a lack of employment and more about pursuing lower-wage occupations to make ends meet.
#graduates
7 days ago
For around 15 hours, immigration detention officers kept Raúl Suárez Herrero confined in a cage slightly larger than a phone booth, where he feared snakes and endured mosquitoes in the middle of Florida swampland, the former detainee alleged.
Suárez, 59, told José Díaz-Balart in an interview for Noticias Telemundo’s “Ahora 360” that he was forced into the cage, measuring 7 feet, 9 inches high and 4 feet, 3 inches square, for praying out loud for an ill young man at “Alligator Alcatraz,” an ICE detention site.
“I feel like I was in ****** ,” Suárez later told NBC News in a phone interview from Mexico, where he was deported.
Suárez spoke days after a Department of Homeland Security watchdog confirmed the use of the phone booth-sized cages at the now-shuttered Florida detention camp in a Sept. 11 report.
“The use of such restrictive ****** es is highly unconventional and does not align with standards for humane treatment,” the report said.
#detention #phone #Florida #report
Suárez, 59, told José Díaz-Balart in an interview for Noticias Telemundo’s “Ahora 360” that he was forced into the cage, measuring 7 feet, 9 inches high and 4 feet, 3 inches square, for praying out loud for an ill young man at “Alligator Alcatraz,” an ICE detention site.
“I feel like I was in ****** ,” Suárez later told NBC News in a phone interview from Mexico, where he was deported.
Suárez spoke days after a Department of Homeland Security watchdog confirmed the use of the phone booth-sized cages at the now-shuttered Florida detention camp in a Sept. 11 report.
“The use of such restrictive ****** es is highly unconventional and does not align with standards for humane treatment,” the report said.
#detention #phone #Florida #report
7 days ago
Seagate Technology Holdings plc (NASDAQ:STX) announced on September 9 that its subsidiary, Seagate HDD Cayman, completed the redemption and exchange of its remaining 3.50% exchangeable senior notes due 2028 on September 8. Approximately $150.7 million of principal was retired through a settlement involving approximately $150.97 million in cash and 1,647,862 ordinary shares.
For notes submitted for exchange, principal was paid in cash, and the exchange obligation above principal was settled in shares, with cash for fractional shares where applicable. The share delivery therefore satisfied an existing contractual obligation.
Seagate Technology Holdings plc (NASDAQ:STX) has removed a 2028 maturity and the remaining settlement uncertainty attached to this instrument. Based on the approximately $150.7 million principal balance and 3.50% coupon, the transaction eliminates roughly $5.3 million of annual stated interest. That is a calculated annualized saving before taxes and any interest income lost on the cash used.
Recent cash generation supports the ability to absorb the payment. As of July 3, 2026, Seagate Technology Holdings plc (NASDAQ:STX) reported $1.704 billion in cash and cash equivalents. Fiscal fourth-quarter free cash flow was $1.118 billion. This company-defined non-GAAP measure is operating cash flow less acquisitions of property, equipment, and leasehold improvements.
The settlement cash payment equals approximately 8.9% of that reported cash balance. Although the July figure predates settlement, it provides a useful measure of the transaction's scale.
#technology #million #exchange
For notes submitted for exchange, principal was paid in cash, and the exchange obligation above principal was settled in shares, with cash for fractional shares where applicable. The share delivery therefore satisfied an existing contractual obligation.
Seagate Technology Holdings plc (NASDAQ:STX) has removed a 2028 maturity and the remaining settlement uncertainty attached to this instrument. Based on the approximately $150.7 million principal balance and 3.50% coupon, the transaction eliminates roughly $5.3 million of annual stated interest. That is a calculated annualized saving before taxes and any interest income lost on the cash used.
Recent cash generation supports the ability to absorb the payment. As of July 3, 2026, Seagate Technology Holdings plc (NASDAQ:STX) reported $1.704 billion in cash and cash equivalents. Fiscal fourth-quarter free cash flow was $1.118 billion. This company-defined non-GAAP measure is operating cash flow less acquisitions of property, equipment, and leasehold improvements.
The settlement cash payment equals approximately 8.9% of that reported cash balance. Although the July figure predates settlement, it provides a useful measure of the transaction's scale.
#technology #million #exchange
7 days ago
Cognyte Software Ltd. (NASDAQ:CGNT) reported on September 9 that revenue for the fiscal second quarter ended July 31, 2026, increased 12.0% to $109.2 million. Total software revenue, comprising software and software services, rose 20.9% to $100.8 million.
Company-defined non-GAAP adjusted EBITDA increased 35.7% to $14.9 million. The measure adds depreciation, amortization, stock-based compensation, restructuring costs, and other specified adjustments to GAAP operating income. Yet quarterly billings fell to $76.3 million from $93.0 million. The central question is whether a more profitable revenue mix can produce stronger cash generation while sustaining future growth.
The portfolio transition is visible in the revenue base. Total software revenue represented more than 92% of sales. Recurring revenue, primarily support contracts and subscription offerings, reached $56.2 million, or 51.4% of total revenue.
For Cognyte Software Ltd. (NASDAQ:CGNT), a larger recurring base could make revenue more predictable and support continued product investment. Renewals also create opportunities to expand customer relationships without rebuilding the sales pipeline from scratch. The benefit depends on retention and expansion within those accounts.
Profitability improved under both accounting measures. GAAP operating margin increased to 4.3% from 2.8%, while adjusted EBITDA margin expanded to 13.6% from 11.3%. That combination strengthens the case that the transition is improving operating economics, even after recognizing expenses excluded from adjusted results.
#gaap #NASDAQ
Company-defined non-GAAP adjusted EBITDA increased 35.7% to $14.9 million. The measure adds depreciation, amortization, stock-based compensation, restructuring costs, and other specified adjustments to GAAP operating income. Yet quarterly billings fell to $76.3 million from $93.0 million. The central question is whether a more profitable revenue mix can produce stronger cash generation while sustaining future growth.
The portfolio transition is visible in the revenue base. Total software revenue represented more than 92% of sales. Recurring revenue, primarily support contracts and subscription offerings, reached $56.2 million, or 51.4% of total revenue.
For Cognyte Software Ltd. (NASDAQ:CGNT), a larger recurring base could make revenue more predictable and support continued product investment. Renewals also create opportunities to expand customer relationships without rebuilding the sales pipeline from scratch. The benefit depends on retention and expansion within those accounts.
Profitability improved under both accounting measures. GAAP operating margin increased to 4.3% from 2.8%, while adjusted EBITDA margin expanded to 13.6% from 11.3%. That combination strengthens the case that the transition is improving operating economics, even after recognizing expenses excluded from adjusted results.
#gaap #NASDAQ
7 days ago
Oddity Tech Ltd. (NASDAQ:ODD) reported second-quarter revenue of approximately $181 million on September 9, down 25% from $241 million a year earlier. Company-defined non-GAAP adjusted EBITDA fell to $13 million from $70 million. This measure excludes net financial income, income taxes, depreciation and amortization, share-based compensation, and certain unusual or nonrecurring items from net income.
Management attributed the disruption primarily to an advertising-algorithm problem affecting IL MAKIAGE. Oddity Tech Ltd. (NASDAQ:ODD) expects third-quarter revenue to decline approximately 5% year over year, with adjusted EBITDA of $18 million to $20 million. The sequential improvement describes a narrowing year-over-year revenue decline.
Management's diagnosis centers on distorted advertising signals that impair IL MAKIAGE's ability to reach suitable customers at acceptable acquisition costs. Oddity Tech Ltd. (NASDAQ:ODD) is testing changes with its largest advertising partner to retrain the algorithm. If those changes restore profitable customer acquisition, the existing brand could recover without a fundamental overhaul of its products.
Other brands provide operating evidence beyond that hypothesis. SpoiledChild delivered double-digit quarterly revenue growth, and management expects at least 35% growth for 2026, approaching $350 million in revenue. Management expects METHODIQ's first-year revenue to exceed SpoiledChild's first-year result.
These results support the argument that Oddity Tech Ltd. (NASDAQ:ODD) can build additional brands using its technology platform. A broader sales base could gradually reduce dependence on IL MAKIAGE, while successful customer retention would help recover upfront advertising spending over multiple purchases.
#revenue #NASDAQ #advertising #expects
Management attributed the disruption primarily to an advertising-algorithm problem affecting IL MAKIAGE. Oddity Tech Ltd. (NASDAQ:ODD) expects third-quarter revenue to decline approximately 5% year over year, with adjusted EBITDA of $18 million to $20 million. The sequential improvement describes a narrowing year-over-year revenue decline.
Management's diagnosis centers on distorted advertising signals that impair IL MAKIAGE's ability to reach suitable customers at acceptable acquisition costs. Oddity Tech Ltd. (NASDAQ:ODD) is testing changes with its largest advertising partner to retrain the algorithm. If those changes restore profitable customer acquisition, the existing brand could recover without a fundamental overhaul of its products.
Other brands provide operating evidence beyond that hypothesis. SpoiledChild delivered double-digit quarterly revenue growth, and management expects at least 35% growth for 2026, approaching $350 million in revenue. Management expects METHODIQ's first-year revenue to exceed SpoiledChild's first-year result.
These results support the argument that Oddity Tech Ltd. (NASDAQ:ODD) can build additional brands using its technology platform. A broader sales base could gradually reduce dependence on IL MAKIAGE, while successful customer retention would help recover upfront advertising spending over multiple purchases.
#revenue #NASDAQ #advertising #expects
7 days ago
The name "351 Exchange" comes from Section 351 of the Internal Revenue Code ("IRC"). Section 351 permits a person to contribute appreciated property in exchange for shares of a newly formed corporation without recognizing a taxable event at the time of transfer, if certain rules are met.
In this application, the property being contributed is shares of stock or ETFs, in exchange for shares of a newly formed corporation, a new ETF.
To qualify, here are a few rules:
1) The contributor must be an eligible participant. In short, most can participate, but C corporations can cause issues, so they are generally excluded.
2) Each contributor must contribute a diversified portfolio. Diversification is defined by the IRS with two tests applied to each contributor's portfolio: Of the contributed portfolio, (1) the weight of the largest position must be no more than 25%, and (2) the sum of the weights of the top 5 positions must be no more than 50%.
#exchange #shares #section #contribute
In this application, the property being contributed is shares of stock or ETFs, in exchange for shares of a newly formed corporation, a new ETF.
To qualify, here are a few rules:
1) The contributor must be an eligible participant. In short, most can participate, but C corporations can cause issues, so they are generally excluded.
2) Each contributor must contribute a diversified portfolio. Diversification is defined by the IRS with two tests applied to each contributor's portfolio: Of the contributed portfolio, (1) the weight of the largest position must be no more than 25%, and (2) the sum of the weights of the top 5 positions must be no more than 50%.
#exchange #shares #section #contribute
7 days ago
Bain Capital Ventures closed its 11th flagship fund at $1.6 billion on Wednesday, betting big on a "post-AGI world" that places AI agents as the chief economic driver of productivity.
The firm has been swapping software for something venture capital has never underwritten: AI-native companies that sell the work itself rather than the technology behind it.
Software startups made up 80% of Fund IX and around 20% of Fund X, said partner Matt Harris. For Fund X, AI-native startups made up 80% of the portfolio.
"The classic software startup is just not being born anymore," Harris said. "These companies where AI is just one feature among many, I think that's thoroughly uninteresting to us and, most importantly, to the most ambitious founders."
BCV defines "post-AGI" as AI agents being as productive as humans. This model's first proof point came in the form of Reserv, an AI-native insurance claims administration startup that the firm incubated with Altai Ventures and other partners. According to Harris, the company hit $100 million in revenue in its second full year. In May, the company raised a $125 million Series C.
#agents
The firm has been swapping software for something venture capital has never underwritten: AI-native companies that sell the work itself rather than the technology behind it.
Software startups made up 80% of Fund IX and around 20% of Fund X, said partner Matt Harris. For Fund X, AI-native startups made up 80% of the portfolio.
"The classic software startup is just not being born anymore," Harris said. "These companies where AI is just one feature among many, I think that's thoroughly uninteresting to us and, most importantly, to the most ambitious founders."
BCV defines "post-AGI" as AI agents being as productive as humans. This model's first proof point came in the form of Reserv, an AI-native insurance claims administration startup that the firm incubated with Altai Ventures and other partners. According to Harris, the company hit $100 million in revenue in its second full year. In May, the company raised a $125 million Series C.
#agents
7 days ago
Core & Main, Inc. (NYSE:CNM) reported quarterly sales of $2.145 billion on September 9, up 2.5%. Company-defined non-GAAP adjusted EBITDA reached $274 million. The measure adjusts consolidated net income for interest, taxes, depreciation and amortization, equity compensation, debt modification and extinguishment losses, offering expenses, and specified other income or expenses.
Consolidated net income rose 6.4% to $150 million, while GAAP diluted earnings per share increased 10% to $0.77. Diluted weighted-average shares declined approximately 2.5% to 193.4 million. Buybacks amplified an improvement that also had an operating foundation.
The company repurchased $169 million of equity during the quarter, against $62 million of operating cash flow. The investment question is whether cash generation can sustain capital returns alongside the spending needed to grow.
Core & Main, Inc. (NYSE:CNM) benefits from demand for essential infrastructure products. Management highlighted municipal demand, fire protection, treatment plants, and data centers as areas of strength. These end markets provide several sources of business even when construction demand is uneven.
Expense discipline also helped. Quarterly selling, general and administrative expenses declined to $301 million from $302 million. Controlling overhead allows modest sales growth to contribute more to earnings. Stronger volumes would make further earnings gains easier to sustain.
#income #main #quarterly
Consolidated net income rose 6.4% to $150 million, while GAAP diluted earnings per share increased 10% to $0.77. Diluted weighted-average shares declined approximately 2.5% to 193.4 million. Buybacks amplified an improvement that also had an operating foundation.
The company repurchased $169 million of equity during the quarter, against $62 million of operating cash flow. The investment question is whether cash generation can sustain capital returns alongside the spending needed to grow.
Core & Main, Inc. (NYSE:CNM) benefits from demand for essential infrastructure products. Management highlighted municipal demand, fire protection, treatment plants, and data centers as areas of strength. These end markets provide several sources of business even when construction demand is uneven.
Expense discipline also helped. Quarterly selling, general and administrative expenses declined to $301 million from $302 million. Controlling overhead allows modest sales growth to contribute more to earnings. Stronger volumes would make further earnings gains easier to sustain.
#income #main #quarterly
7 days ago
Wealthfront Corporation (NASDAQ:WLTH) reported on September 9 that fiscal second-quarter revenue increased 1% to $91.9 million, despite platform ***** ets rising 12% to $99 billion. The quarter ended July 31, 2026. Funded clients increased 14% to 1.51 million, and platform ***** ets surpassed $100 billion by the end of August.
Platform ***** ets measure financial ***** ets held in client accounts. Their growth reflects both net deposits and market movements, so the headline increase does not represent new client money alone.
Adjusted EBITDA declined 15% to $38.1 million, with its margin falling to 41% from 49%. Wealthfront Corporation (NASDAQ:WLTH) defines this non-GAAP measure as net income excluding interest expense, income taxes, depreciation and amortization, stock-based compensation, fair-value changes in convertible notes, warrant liabilities and simple agreements for future equity, and nonrecurring expenses. Adjusted EBITDA margin divides that figure by revenue.
The advisory business is translating ***** et growth into revenue. Investment advisory ***** ets increased 30% to $54.1 billion, while advisory revenue rose 31% to $28.8 million. Those results show that the expanding investment business is generating a larger recurring fee stream.
For Wealthfront Corporation (NASDAQ:WLTH), this creates an opportunity to deepen client relationships as savings move toward longer-term investment goals. A growing advisory base could support more durable relationships, provided clients remain invested and continue contributing.
#wealthfront #revenue #platform #investment
Platform ***** ets measure financial ***** ets held in client accounts. Their growth reflects both net deposits and market movements, so the headline increase does not represent new client money alone.
Adjusted EBITDA declined 15% to $38.1 million, with its margin falling to 41% from 49%. Wealthfront Corporation (NASDAQ:WLTH) defines this non-GAAP measure as net income excluding interest expense, income taxes, depreciation and amortization, stock-based compensation, fair-value changes in convertible notes, warrant liabilities and simple agreements for future equity, and nonrecurring expenses. Adjusted EBITDA margin divides that figure by revenue.
The advisory business is translating ***** et growth into revenue. Investment advisory ***** ets increased 30% to $54.1 billion, while advisory revenue rose 31% to $28.8 million. Those results show that the expanding investment business is generating a larger recurring fee stream.
For Wealthfront Corporation (NASDAQ:WLTH), this creates an opportunity to deepen client relationships as savings move toward longer-term investment goals. A growing advisory base could support more durable relationships, provided clients remain invested and continue contributing.
#wealthfront #revenue #platform #investment
7 days ago
Sunbelt Rentals Holdings, Inc. (NYSE:SUNB) reported on September 9 that fiscal first-quarter revenue increased 11.2% to $3.115 billion, including $2.927 billion of rental revenue, up 12.5%. The quarter ended July 31, 2026.
Management raised fiscal 2027 rental-revenue growth guidance to 7% through 10%, while increasing planned net rental-equipment capital expenditures to $2.4 billion through $2.8 billion. Demand supports expansion, but investors need to ****** s how much cash remains after funding the fleet.
North America Specialty rental revenue grew 25.3%, giving Sunbelt Rentals Holdings, Inc. (NYSE:SUNB) a strong source of growth beyond general equipment rentals. Specialized services can deepen customer relationships and create opportunities to supply several needs on the same project.
The company estimated that the FIFA World Cup contributed 2.5 percentage points to quarterly rental-revenue growth. Serving complex events demonstrates the commercial value of a broad equipment network. The investment opportunity is to turn that capability into recurring work across industrial, energy and construction customers.
Adjusted EBITDA increased 8.7% to $1.315 billion. This company-defined non-GAAP measure adds taxes, net interest, depreciation, amortization, stock-based compensation and specified restructuring costs to net income. Its margin is adjusted EBITDA divided by revenue.
#rentals
Management raised fiscal 2027 rental-revenue growth guidance to 7% through 10%, while increasing planned net rental-equipment capital expenditures to $2.4 billion through $2.8 billion. Demand supports expansion, but investors need to ****** s how much cash remains after funding the fleet.
North America Specialty rental revenue grew 25.3%, giving Sunbelt Rentals Holdings, Inc. (NYSE:SUNB) a strong source of growth beyond general equipment rentals. Specialized services can deepen customer relationships and create opportunities to supply several needs on the same project.
The company estimated that the FIFA World Cup contributed 2.5 percentage points to quarterly rental-revenue growth. Serving complex events demonstrates the commercial value of a broad equipment network. The investment opportunity is to turn that capability into recurring work across industrial, energy and construction customers.
Adjusted EBITDA increased 8.7% to $1.315 billion. This company-defined non-GAAP measure adds taxes, net interest, depreciation, amortization, stock-based compensation and specified restructuring costs to net income. Its margin is adjusted EBITDA divided by revenue.
#rentals
7 days ago
Corn futures saw some late session strength as contracts closed with losses of 1 ½ to 2 ¼ cents across the board on Wednesday. The CmdtyView national average Cash Corn price was down 1 1/2 cents at $4.89.
The weekly EIA report showed ethanol production at 1.099 million barrels per day in the week of 9/4, steady with the week prior. That is still 4.17% above the same week last year. Stocks saw a 33,000 barrel increase to 25.22 million barrels, which is 11.58% above the same week last year. Refiner inputs of ethanol were up 3,000 barrels per day to 911,000 barrels per day, with exports up 14,000 barrels per day to 161,000 bpd.
Coffee Prices Pressured by Improved Global Supply Outlook
Cocoa Prices Consolidate Below 11.5-Month Highs
Signs of Improving Global Supplies Weigh on Coffee Prices
#coffee #cents #ethanol #million
The weekly EIA report showed ethanol production at 1.099 million barrels per day in the week of 9/4, steady with the week prior. That is still 4.17% above the same week last year. Stocks saw a 33,000 barrel increase to 25.22 million barrels, which is 11.58% above the same week last year. Refiner inputs of ethanol were up 3,000 barrels per day to 911,000 barrels per day, with exports up 14,000 barrels per day to 161,000 bpd.
Coffee Prices Pressured by Improved Global Supply Outlook
Cocoa Prices Consolidate Below 11.5-Month Highs
Signs of Improving Global Supplies Weigh on Coffee Prices
#coffee #cents #ethanol #million
